Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
|Articles|April 5, 2021
- Pharmaceutical Technology's In the Lab eNewsletter 04-07-2021
- Volume 16
- Issue 4
Sotera Health to Acquire BioScience Laboratories to Expand its Antimicrobial and Antiviral Testing Capabilities
Author(s)Pharmaceutical Technology Editors
The acquisition will expand the antimicrobial and antiviral testing capabilities of Sotera’s Nelson Labs business in the US.
Advertisement
Sotera Health, a US-based provider of sterilization, lab-testing, and advisory services, announced on March 10, 2021 that it has acquired BioScience Laboratories, a topical antimicrobial product testing company located in the US.
The acquisition will expand the antimicrobial and antiviral testing capabilities of Sotera’s Nelson Labs business in the US, Sotera said in a company press release. Financial details of the acquisition were not disclosed.
“BioScience Laboratories is premier provider of antimicrobial testing services; known for its testing of consumer hand sanitizers, pre-operating hand-wash, and hard surface disinfectants. It is also recognized for its strong relationships with its customers and regulators,” said Michael B. Petras Jr., chairman and CEO of Sotera Health, in the press release. “This acquisition will expand and further strengthen our antimicrobial and virology lab testing capabilities. We welcome BioScience Laboratories’ strong management and expert staff as they join us in our mission, safeguarding global health.”
Source:
Articles in this issue
over 5 years ago
Pandemic Spurs Cybersecurity Risks in Laboratoriesover 5 years ago
Toxicology: Guaranteeing Drugs are Safe for Peopleover 5 years ago
Academic Lab to Develop a Nasal Spray Vaccine for COVID-19over 5 years ago
LabConnect to Expand its Tennessee Facilityover 5 years ago
LabVantage Announces New CEOover 5 years ago
Roche Launches Compact Analyzer for Small-to-Medium-Sized LabsAdvertisement
Related to this article
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
AAPS PharmSci 360 2026: Roller-Compacted Formulations
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5